Arachidonic Acid Metabolism in Carotid Stenosis Plaque in Diabetic Patients
MASCADI
1 other identifier
observational
204
1 country
1
Brief Summary
Diabetes is associated with an increased risk of cardiovascular complications, as a reflection of the chronic inflammatory status. Monocytes-macrophages in diabetic subjects present impaired arachidonic acid metabolism. Moreover, atheromatous plaques in diabetic subjects seem to be significantly enriched in 2-AA-LPC (2-arachidonoyl-lysophosphatidylcholine) and are more inflammatory and more likely to rupture than are plaques in non-diabetic subjects. We therefore hypothesize that this vulnerability of atheromatous plaques in diabetic subjects could be explained by impaired 2-AA-LPC metabolism within the plaque.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 13, 2017
CompletedFirst Submitted
Initial submission to the registry
June 21, 2017
CompletedFirst Posted
Study publicly available on registry
June 29, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 11, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 11, 2020
CompletedFebruary 9, 2026
February 1, 2026
3.7 years
June 21, 2017
February 5, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in arachidonic acid metabolism of atheromatous plaques from diabetic versus non-diabetic subjects
Baseline
Study Arms (2)
Diabetics
Non-diabetics
Interventions
a carotid sample collected during surgery
Eligibility Criteria
Diabetic and non-diabetic patients with carotid stenosis who undergo surgery
You may qualify if:
- Patients who have provided explicit consent
- Patients older than 18 years
- Patients about to undergo surgery for carotid stenosis
- Haemoglobin ≥ 7g/dl at the time the sample is taken
- Respect the maximum volume of blood taken (treatment + research) in 30 days
- SPECIFIC TO DIABETICS
- \- Patients with type 1 or 2 diabetes diagnosed more than 6 months earlier
You may not qualify if:
- Patients under guardianship
- Patients without health insurance cover
- Pregnant or breast-feeding women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chu Dijon Bourgogne
Dijon, 21000, France
Related Publications (1)
Menegaut L, Laubriet A, Crespy V, Leleu D, Pilot T, Van Dongen K, de Barros JP, Gautier T, Petit JM, Thomas C, Nguyen M, Steinmetz E, Masson D. Inflammation and oxidative stress markers in type 2 diabetes patients with Advanced Carotid atherosclerosis. Cardiovasc Diabetol. 2023 Sep 14;22(1):248. doi: 10.1186/s12933-023-01979-1.
PMID: 37710315RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 21, 2017
First Posted
June 29, 2017
Study Start
April 13, 2017
Primary Completion
December 11, 2020
Study Completion
December 11, 2020
Last Updated
February 9, 2026
Record last verified: 2026-02